Life Sciences

  • May 27, 2026

    Squires Says Sun PGR Petition Denied For Not Naming Parent

    Sun Pharmaceutical Industries Inc.'s failure to name its parent company in its challenge to a Biofrontera Inc. patent was why its request for review was rejected early, U.S. Patent and Trademark Office Director John Squires has said.

  • May 27, 2026

    Pierce Atwood Rips Billionaire's 'Absurd' Suit Over Asset Sale

    Pierce Atwood and two attorneys urged a Massachusetts federal judge to reject a Ukrainian billionaire's suit blaming them for a $1.8 million damages order in investor litigation over the billionaire's failed biotech company, saying his own wrongdoing led to the judgment.

  • May 26, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court this past week handled a broad mix of cross-border corporate control disputes, merger settlements, startup equity fights, advancement claims and board oversight litigation, while also weighing fallout from high-profile deals involving Microsoft Corp., The Boeing Co. and Nikola Corp.

  • May 26, 2026

    9th Circ. Backs Reinstating DEI Grants Nixed By Trump

    The Ninth Circuit on Tuesday partially upheld a lower court's preliminary injunction and class certification orders in litigation from University of California researchers against President Donald Trump, backing the reinstatement of grants terminated due to presidential orders against diversity, equity and inclusion initiatives while reversing the injunction for those grants that were rescinded without explanation.

  • May 26, 2026

    Conn. Drug Price Law Still Allows Hikes, 2nd Circ. Told

    Wholesale distributors that abide by Connecticut's drug price cap law can hike the cost of their other products to ensure they don't suffer losses, the state told the Second Circuit Tuesday, raising the ire of the companies trying to invalidate the new statute.

  • May 26, 2026

    Beasley Allen Fails To Overturn J&J Talc Disqualification

    A New Jersey federal judge affirmed the Beasley Allen Law Firm's disqualification from multidistrict litigation over Johnson & Johnson's talcum powder on Tuesday, determining that the firm has failed to provide a valid reason to back its attempt at a stay and temporary reinstatement into the matter.

  • May 26, 2026

    Squires' Institution Flips Are Increasing Uncertainty At PTAB

    U.S. Patent and Trademark Office Director John Squires has created a record low institution rate at the Patent Trial and Appeal Board, and attorneys say it's becoming increasingly clear that even an initial approval from the director may not last.

  • May 26, 2026

    Eli Lilly Expands Vaccine Push With Deals Worth Up To $3.8B

    Eli Lilly and Co. said Tuesday it will buy three companies involved in vaccine development — Curevo Inc., LimmaTech Biologics AG, and Vaccine Company Inc. — for a total of up to roughly $3.83 billion.

  • May 22, 2026

    Law360 Reveals Titans Of The Plaintiffs Bar

    This past year, 10 lawyers across the country at plaintiffs' firms big and small helped secure millions of dollars in settlements and verdicts for their clients, going up against powerful defendants like Google, Monsanto and the Trump administration, earning the attorneys recognition as Law360's Titans of the Plaintiffs Bar for 2026.

  • May 22, 2026

    J&J 's 'Pure' Baby Powder Ads Were Pure Lies, Jury Told

    A University of Toronto marketing professor on Friday told a Los Angeles jury considering bellwether claims that Johnson & Johnson's talc products caused deadly ovarian cancer in three women that the company advertised its talc as "pure" and safe even though its leaders fretted for decades that it could pose health risks.

  • May 22, 2026

    Health Workers Say US Solicitor Wrong In NY Vax Case

    The U.S. solicitor general's position that the nation's highest court shouldn't take up a religious bias suit over a New York state COVID-19 vaccine mandate for healthcare workers incorrectly claimed that accommodations were obtainable, the mandate's challengers told the justices Friday.

  • May 22, 2026

    Healthcare Orgs Push DC Court To Block Student Loan Caps

    Professional organizations representing nurses, therapists, public health workers and educators urged a District of Columbia federal court on Thursday to block a rule by the U.S. Department of Education restricting federal student loan eligibility for a host of degree programs, arguing it exceeded the department's authority.

  • May 22, 2026

    Opioid Plaintiffs Want Sanctions Over McKinsey Deletions

    A group of plaintiffs in multidistrict litigation against McKinsey & Co. is urging a California federal court to sanction the company for deleting communications with Purdue Pharma and other opioid-makers, saying the court should enter a default judgment against the consulting firm.

  • May 22, 2026

    Don't Miss It: Cooley, Simpson Thacher Steer Hot Deals

    A lot can happen in the world of mergers and acquisitions and equity fundraising over the course of a couple of weeks, and it's difficult to keep up with all the deals.

  • May 22, 2026

    Consumer Drops TCPA Suit Against Colo. Supplement Co.

    A Colorado dietary supplement company accused of bombarding consumers with unsolicited telemarketing texts has been let off the hook after the woman who sued it voluntarily dropped the case, according to a filing in Colorado federal court.

  • May 22, 2026

    Trump's Melding Of Politics, Antitrust Hard To Roll Back

    Environmental initiatives, diversity programs, anti-misinformation efforts and gender-affirming care have become central targets for President Donald Trump's antitrust enforcers in what observers say is an increasing trend of politically tinged competition enforcement.

  • May 21, 2026

    PBM Swaps Cravath For WilmerHale In Price-Fixing Suit

    Pharmacy benefit manager Prime Therapeutics LLC has replaced counsel Cravath Swaine & Moore LLP with WilmerHale and another firm in an antitrust case in Michigan federal court brought by the state's attorney general.

  • May 21, 2026

    J&J Used Ellipsis To Nix Asbestos In Report To FDA, Jury Told

    Johnson & Johnson used an ellipsis to eliminate a professor's finding of asbestos in its talc in a report submitted to the U.S. Food and Drug Administration, according to a video deposition shown Thursday to a California jury considering bellwether claims over three women's deadly ovarian cancer.

  • May 21, 2026

    9th Circ. Says Judge Overstepped In Fluoride Risk Case

    A Ninth Circuit panel scrapped a ruling that directed the U.S. Environmental Protection Agency to take action to address potentially unsafe levels of drinking water fluoridation, concluding a California federal judge improperly commandeered the case.

  • May 21, 2026

    NFL Teams Valued At $9B In Stake Sales, And Other Rumors

    Two reported NFL stake sales this past week highlight the continued surge in professional sports valuations, fueled in part by the entry of private equity investors.

  • May 21, 2026

    Insurer Can't Nix Counterclaims In $1.8M Judgment Dispute

    A North Carolina federal judge found that a life sciences company's insurer can't avoid counterclaims brought by a former patent holder asserting that the carrier must cover a $1.77 million judgment entered against the company's executives after they were accused of making misrepresentations about taking the company public.

  • May 21, 2026

    UCB Staves Off Seizure Drug Competition After Bench Trial

    UCB Inc. has persuaded a Delaware federal judge to uphold patents covering its seizure medication Nayzilam, a major win given that generic-drug maker Cipla Ltd. already admitted to infringement.

  • May 21, 2026

    9th Circ. Told To Reject J&J Unit's $442M Antitrust Appeal

    Cardiac catheter refurbisher Innovative Health urged the Ninth Circuit to reject the appeal from Johnson & Johnson's Biosense Webster unit seeking to upend its $442 million antitrust judgment, saying the lower court rightly found that Biosense forced hospitals to avoid refurbished catheters in favor of its own.

  • May 21, 2026

    Vape Sellers Say Pa. E-Cig Law Usurps FDA Authority

    Vape companies are looking to stop a Pennsylvania law that would effectively ban most e-cigarettes, claiming in a federal lawsuit that the statute is unconstitutional, would destroy roughly $2 million of their inventory and targets products that federal regulators say helps smokers quit.

  • May 21, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Virginia's governor vetoed legislation to establish adult-use marijuana sales, keeping the state in cannabis legal limbo; Illinois lawmakers introduced legislation to rein in hemp products, aligning state policy with an upcoming shift in federal law; and Louisiana lawmakers sent a bill to the governor that would allow terminally ill patients to access medical marijuana in healthcare facilities. Here are the major moves in cannabis and psychedelics legislation from the past week.

Expert Analysis

  • Regulatory Uncertainty Ahead For Organ Transplant System

    Author Photo

    Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.

  • Key False Claims Act Trends From The Last Year

    Author Photo

    The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.

  • Opinion

    It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs

    Author Photo

    The U.S. Food and Drug Administration's decision this month to order removal of warnings about the risk of suicidal thoughts from GLP-1 weight-loss drugs is premature — and from a safety and legal standpoint, the downside of acting too soon could be profound, says Sean Domnick at Rafferty Domnick.

  • Series

    Hosting Exchange Students Makes Me A Better Lawyer

    Author Photo

    Opening my home to foreign exchange students makes me a better lawyer not just because prioritizing visiting high schoolers forces me to hone my organization and time management skills but also because sharing the study-abroad experience with newcomers and locals reconnects me to my community, says Alison Lippa at Nicolaides Fink.

  • FDA's 2025 Enforcement Scorecard Highlights Data Focus

    Author Photo

    The U.S. Food and Drug Administration's increased enforcement activity in 2025 was driven by artificial intelligence and a focus on foreign manufacturers, necessitating proactive compliance strategies for an environment that is increasingly reliant on data, say attorneys at Reed Smith.

  • How A 1947 Tugboat Ruling May Shape Work Product In AI Era

    Author Photo

    Rapid advances in generative artificial intelligence test work-product principles first articulated in the U.S. Supreme Court’s nearly 80-year-old Hickman v. Taylor decision, as courts and ethics bodies confront whether disclosure of attorneys’ AI prompts and outputs would reveal their thought processes, say Larry Silver and Sasha Burton at Langsam Stevens.

  • Navigating Privilege Law Patchwork In Dual-Purpose Comms

    Author Photo

    Three years after the U.S. Supreme Court declined to resolve a circuit split in In re: Grand Jury, federal courts remain split as to when attorney-client privilege applies to dual-purpose legal and business communications, and understanding the fragmented landscape is essential for managing risks, say attorneys at Covington.

  • How AI Drafting Should Transform Patent Filing Strategies

    Author Photo

    As agentic artificial intelligence reduces the time and expense required to draft and file patents, companies should shift focus away from rationing drafting hours and more toward governing optionality, says Ian Schick at Paximal.

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

  • Series

    The Law Firm Merger Diaries: Forming Measurable Ties

    Author Photo

    Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.

  • AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny

    Author Photo

    Virginia Attorney General Jason Miyares' recent investigation into insulin manufacturers and pharmacy benefit managers for allegedly colluding to artificially inflate insulin prices reflects a broader trend to leverage consumer protection authority in high-impact healthcare matters, and the upcoming leadership change is unlikely to diminish scrutiny in this area, says Chuck Slemp at Cozen O'Connor.

  • FDA's AI Deployment Brings New Potential And Risks

    Author Photo

    The U.S. Food and Drug Administration's recent announcement about making agentic artificial intelligence tools available to agency employees may portend accelerated regulatory timelines and lower costs for drug companies and consumers, but potential errors and biases will necessitate additional safeguards, says Angela Silva at Lewis Brisbois.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.